Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Investigational New DrugsOpen Access

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAmelia Kierasińska-KałkaARAdrianna RutkowskaJMJacek Mularski

Discussion

Loading...

Member takes

Overview

Novel fluorescent tyrosine kinase inhibitors target mutant EGFR proteins in cancer, implying diagnostic and therapeutic potential.

Key Points

  • This research aims to design a fluorescent EGFR tyrosine kinase inhibitor capable of targeting mutant proteins associated with cancer.
  • Conducted docking studies to evaluate binding affinity to EGFR mutants.
  • Developed a new afatinib analog with intrinsic fluorescence properties.
  • Assessed in vitro fluorescence performance of the synthesized compounds.
  • The novel afatinib analog demonstrated effective covalent inhibition of EGFR mutants.
  • In vitro tests showed significant fluorescent properties, facilitating detection of mutated EGFR.
  • The compound enhanced diagnostic capabilities and may support photodynamic therapy development.

Cite This Study

Kierasińska-Kałka et al. (2026) studied this question.

synapsesocial.com/papers/6a65a2e2d3aea3239cd76390https://doi.org/10.1007/s10637-026-01625-z
View Full Paper
Ask AI
Bookmark
Share